A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Celgene Corporation100 enrolled

Overview

To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Multiple Myeloma

Interventions

CC-5013DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* History of histologically documented multiple myeloma with relapsed or resistant disease * Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. * Signed written informed consent and willingness to meet follow-up schedule and study procedure obligations

Locations (1)

Myeloma Institute University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.